Mitomycin Substipharm

Mitomycin, the active ingredient in Mitomycin Substipharm, is an antineoplastic antibiotic presented as a sterile solution for intravenous and intravesical use. It treats various solid tumors and is used in oncology patients.\n\nGNH India supplies Mitomycin Substipharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Mitomycin is an antineoplastic antibiotic used in the treatment of solid tumors, particularly those responsive to DNA‑cross‑linking agents.\n\nBladder cancer (intravesical): reduces tumor recurrence after transurethral resection.\nGastric carcinoma (systemic): provides cytotoxic activity against advanced disease.\nPancreatic carcinoma (systemic): used in combination regimens for metastatic disease.

Adverse reactions to Mitomycin may vary in frequency and severity.\n\nCommon Side Effects:\n- Nausea and vomiting\n- Myelosuppression (decreased blood cell counts)\n- Alopecia (hair loss)\n- Fatigue\n\nSerious or Rare Side Effects:\n- Severe bone marrow suppression leading to pancytopenia\n- Pulmonary toxicity (interstitial pneumonitis)\n- Renal toxicity (acute kidney injury)

Mitomycin requires careful monitoring and specific safety measures before and during therapy.\n\nRenal function: assess baseline and monitor during therapy.\nHematologic status: monitor blood counts regularly.\nPregnancy: avoid use unless benefits outweigh risks.\nConcurrent radiation: use caution due to enhanced toxicity.\nStore at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mitomycin may interact with other medicines, altering its safety or effectiveness.\n\nMajor Interactions (Avoid):\n- Azathioprine: increased myelosuppression.\n- Warfarin: enhanced anticoagulant effect.\n- Cyclophosphamide: additive bone marrow toxicity.\n\nModerate Interactions (Monitor Closely):\n- NSAIDs: may increase nephrotoxicity.\n- Aminoglycoside antibiotics: potential renal impairment.